![Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?](https://evolution-bio.com/wp-content/uploads/2016/08/160822-pfizer-medivation-bio.jpg)
Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation by Sanofi, as well
![Evolution Infographic: The Rise & Diversification of Biologics](https://evolution-bio.com/wp-content/uploads/2016/02/160223-biologics-featured.jpg)
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and
![Evolution Analysis – Google, Sanofi, Novartis and the Race to Improve Diabetes Health Outcomes](https://evolution-bio.com/wp-content/uploads/2016/04/150910-news-google-sanofi-diabetes.jpg)
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of
![Merck, Sanofi, Syngenta & GSK announce full year results for 2014](https://evolution-bio.com/wp-content/uploads/2016/04/gsk-sanofi-merck-syngenta.jpg)
Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates